Ram Selvaraju


Rodman & Renshaw Analyst Cuts Price Target For Valeant Pharmaceuticals Intl Inc (VRX) Following 2Q:16 Miss

Rodman & Renshaw analyst Ram Selvaraju weighed in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) after the drug maker released its second-quarter results and reaffirmed its …

Rodman & Renshaw Weighs In on Synergy Pharmaceuticals Inc (SGYP) Ahead of Upcoming Phase 3 Data

Rodman & Renshaw analyst Ram Selvaraju weighed in today with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ahead of the the upcoming Phase 3 …

Synergy Pharmaceuticals Inc (SGYP)’s Plecanatide Stays Compelling Despite Competitive Pressures: Rodman & Renshaw

In a research report released today, Rodman & Renshaw analyst Ram Selvaraju reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), with a …

Rodman & Renshaw Initiates Buy on Synergy Pharmaceuticals Inc; Sees 228% Upside for the Stock

In a research report released yesterday, Rodman & Renshaw analyst Ram Selvaraju initiated coverage on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), with a Buy rating and price …

MLV Initiates Buy on Catalyst Pharmaceuticals Inc; Sees 251% Upside For The Stock

In a research report released Wednesday, MLV & Co. analyst Ram Selvaraju initiated coverage on shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) with a Buy …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts